Pfizer, BioNTech seek FDA authorization of COVID-19 booster for children

Pfizer and BioNTech said Thursday that they will be asking the FDA to authorize a COVID-19 booster dose for children aged 5 to 11 years.
The announcement came in a press release reporting the results of a phase 2/3 clinical trial that showed a booster dose of the vaccine produced a robust immune response, with no new safety signals.
“These data reinforce the potential function of a third dose of the vaccine in maintaining high levels of protection against the virus in this age group,” the companies said.
The clinical trial included 140 children aged 5 to 11 years who received a

Pfizer and BioNTech said Thursday that they will be asking the FDA to authorize a COVID-19 booster dose for children aged 5 to 11 years.
The announcement came in a press release reporting the results of a phase 2/3 clinical trial that showed a booster dose of the vaccine produced a robust immune response, with no new safety signals.
“These data reinforce the potential function of a third dose of the vaccine in maintaining high levels of protection against the virus in this age group,” the companies said.
The clinical trial included 140 children aged 5 to 11 years who received a